Eli Lilly and Company LLY, last week, gained the much-anticipated FDA approval for its once-daily oral GLP-1 pill orforglipron for treating obesity. The pill will be marketed under the name Foundayo.

A review of microscopic colitis, a chronic, intermittent inflammatory bowel disease that predominantly affects older women and typically presents with frequent watery, non-bloody stools.

Though it may seem daunting to make the dietary changes necessary after an IBD diagnosis, these expert ideas will make it ...

For millions with IBD, eating can be complicated. But these empowering, expert-backed tips help bring confidence and control ...

Single agent duvelisib demonstrated clinically meaningful response rates, including a substantial proportion of complete responses, in a heavily ...

In turbulent times, experts recommend building up a store of food if possible – focusing on long-life, no-cook items People should have an emergency stockpile of food in their homes in case conflicts, ...

Personal Independence Payment (PIP) is paid every four weeks, with maximum combined payments reached £779.

GLP-1 medications treat type 2 diabetes and obesity by mimicking a hormone that helps manage blood sugar. A balanced diet can improve how well these medications work. The best foods to eat while on ...

What you eat is an important part of treatment when you’re using semaglutide for type 2 diabetes or obesity. To support semaglutide’s effects and reduce digestive side effects, focus on prebiotic ...

Biologic therapy within a year of diagnosis could decrease risk for disease progression among patients with ulcerative ...

Filing acceptance based on Phase III ALLEGORY data for Gazyva showing a significant reduction in disease activity compared with placebo in people with systemic lupus erythematosus (SLE)If approved, ...